Pfizer, Adaptive Biotechnologies Partner in Translational Research
By

Pfizer Inc. and Adaptive Biotechnologies Corporation have entered into a translational research collaboration for sequencing of the adaptive immune system to advance Pfizer's growing immuno-oncology franchise. Under the terms of the agreement, Pfizer and Adaptive will seek to combine drug development and platform technology biomarker expertise to identify patients who may preferentially benefit from immunotherapy.

Adaptive Biotechnologies uses high-throughput sequencing and expert bioinformatics to profile T-cell and B-cell receptors. Adaptive translates immunosequencing discoveries into clinical diagnostics and therapeutic development. Understanding and reliably measuring each patient's immune response to their cancer before and after therapy is critical to defining the most appropriate immunotherapy for that patient. Adaptive's immunosequencing platform quantitatively and reproducibly measures the patient's immune-cell repertoire, providing a translational tool to accelerate Pfizer's immuno-oncology biomarker and drug development programs.

Source: Pfizer

Leave a Reply

Your email address will not be published.